Federal contractor · PHILADELPHIA, PA

THE INSTITUTE FOR CANCER RESEARCH

THE INSTITUTE FOR CANCER RESEARCH received -$16.8K in federal contract obligations in FY2026, on 6 awards. Since FY2017: $8.6M. Its largest customer was National Institutes of Health (-$16.8K). It also received $28.5M in federal grants and other assistance in FY2026.

Obligations · FY2026
-$16.8K
New awards
6
Sole-source
—
Single offer
—
UEI
FF1XVJMDYVR1
Other than small businessNonprofit
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 339KFY2017
  2. 617.2KFY2018
  3. 368.4KFY2019
  4. 804.8KFY2020
  5. 16KFY2021
  6. 2.6MFY2022
  7. 2.2MFY2023
  8. 1.7MFY2024
  9. 0FY2025
  10. -16.8KFY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health-$16.8K0.0%
    6 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION$2.1M
    National Institutes of Health· Philadelphia County, PA· Research & development· Jun 13, 2022 – May 12, 2026· 75N91022F00001
  2. TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER$1.2M
    National Institutes of Health· Philadelphia County, PA· Research & development· May 17, 2022 – Jul 7, 2026· 75N91022F00002
  3. PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA$1.2M
    National Institutes of Health· Philadelphia County, PA· Research & development· May 1, 2023 – Apr 7, 2026· 75N91023F00003
  4. COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS$1M
    National Institutes of Health· Philadelphia County, PA· Research & development· Jul 7, 2023 – Jan 29, 2026· 75N91023F00001
  5. TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTION PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS$948.4K
    National Institutes of Health· Philadelphia County, PA· Research & development· Sep 15, 2022 – Dec 11, 2025· 75N91022F00003
  6. THE ELNITSKI LAB IS PURCHASING NORMAL, LIVER, AND PROSTATE CANCER PATIENT PLASMA.[21-004028]$0
    National Institutes of Health· Philadelphia County, PA· Health & medical· May 3, 2021 – Jul 6, 2026· 75N92E21P00142

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

THE INSTITUTE FOR CANCER RESEARCH received $28.5M in federal assistance in FY2026, on 91 actions (3 new awards), −15% vs FY2025. Its largest program was 93.395 · Cancer Treatment Research ($5.1M).

Assistance · FY2026
$28.5M
New awards
3
Actions
91
Since FY2021
$160.3M

Assistance by fiscal year

  1. 20.6MFY2021
  2. 22.3MFY2022
  3. 29.1MFY2023
  4. 26.2MFY2024
  5. 33.5MFY2025
  6. 28.5MFY2026

By type

  1. Grants$28.5M100%

Top programs

  1. 93.395 · Cancer Treatment Research$5.1M18%
  2. 93.396 · Cancer Biology Research$4.7M16%
  3. 93.855 · Allergy and Infectious Diseases Research$3.9M14%
  4. 93.393 · Cancer Cause and Prevention Research$3.6M12%
  5. 93.859 · Biomedical Research and Research Training$3.1M11%
  6. 93.397 · Cancer Centers Support Grants$2.8M9.8%
  7. 93.307 · Minority Health and Health Disparities Research$2.4M8.5%
  8. 93.399 · Cancer Control$1.5M5.3%

Awarding agencies

  1. National Institutes of Health$28.5M100%
    Department of Health and Human Services

Largest awards

  1. COMPREHENSIVE CANCER CENTER PROGRAM AT FOX CHASE$73.2M
    93.397 · Cancer Centers Support Grants· National Institutes of Health· Project grant· Jan 6, 2021 – Jun 26, 2026· P30CA006927
  2. MOLECULAR BASIS FOR GAMMA/DELTA T LINEAGE SPECIFICATION$24M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 5, 2021 – Aug 19, 2026· P01AI102853
  3. MECHANISM, FUNCTION, AND EXPLOITATION OF INFLUENZA A VIRUS-ACTIVATED CELL DEATH$6.8M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 4, 2021 – Jan 22, 2026· R01AI135025
  4. CANCER PREVENTION-INTERCEPTION TARGETED AGENT DISCOVERY PROGRAM AT FOX CHASE CANCER CENTER - PROJECT SUMMARY - OVERALL HEREDITABLE…$6.8M
    93.399 · Cancer Control· National Institutes of Health· Cooperative agreement· Sep 1, 2022 – Sep 9, 2026· U54CA272686
  5. STRUCTURAL BIOINFORMATICS OF PROTEINS AND PROTEIN COMPLEXES AND APPLICATIONS TO CANCER BIOLOGY$6.3M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Mar 15, 2021 – Apr 17, 2026· R35GM122517
  6. NOVEL REGULATORY MECHANISMS UNDERLYING INSIDE-OUT INTEGRIN ACTIVATION$5M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Dec 3, 2021 – Mar 20, 2026· R35GM119560

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

  • Sub-grants: $867.7K (7 subawards)

6 primes

  1. FRED HUTCHINSON CANCER CENTER$441.9K51%
    SEATTLE, WA · 2 subawards
  2. THE CHILDREN'S HOSPITAL OF PHILADELPHIA$229.6K26%
    PHILADELPHIA, PA · 1 subaward
  3. OREGON STATE UNIVERSITY$86.5K10.0%
    CORVALLIS, OR · 1 subaward
  4. ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC.$58K6.7%
    PHILADELPHIA, PA · 1 subaward
  5. BROWN UNIVERSITY$39.1K4.5%
    PROVIDENCE, RI · 1 subaward
  6. THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER$12.5K1.4%
    HOUSTON, TX · 1 subaward

By fiscal year

  • FY2021: $0 paid out · $3.8M received
  • FY2022: $0 paid out · $2.3M received
  • FY2023: $0 paid out · $3.3M received
  • FY2024: $0 paid out · $2.6M received
  • FY2025: $0 paid out · $1.4M received
  • FY2026: $0 paid out · $867.7K received

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 9, 2026, loaded Oct 9, 2026 · Subawards loaded from FY2021.

Teaming partners

Companies this company reported paying, primes that reported paying it, from FFATA subaward reports.

Companies it pays

No subawards reported to other companies.

Primes that pay it

32 companies · $14.2M reported

  1. THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY$2.6M
    PHILADELPHIA, PA · 10 subawards
  2. YALE UNIV$1.9M
    NEW HAVEN, CT · 8 subawards
  3. THOMAS JEFFERSON UNIVERSITY$1.8M
    PHILADELPHIA, PA · 5 subawards

Showing the top 3 of each list. Open the profile for potential partners and the full lists.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 9, 2026, loaded Oct 9, 2026 · Subawards loaded from 2021.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. GREFFEX INC$1.7M−100% in FY2026
    AURORA, CO · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. AMPERSAND BIOSCIENCES LLC$1.7M−100% in FY2026
    LAKE CLEAR, NY · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. IDAHO HOSPITAL ASSOCIATION INC$1.8M+19% in FY2026
    BOISE, ID · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.